Search

Author/Creator Lenz, Robert A

1. A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial. Issue 5 (8th May 2017)

Authors:
Dodick, David; Ashina, Messoud; Kudrow, David; Lanteri-Minet, Michel; Osipova, Vera; Palmer, Kerry; Picard, Hernan; Mikol, Daniel D; Lenz, Robert A
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 88:Issue 5(2017)
Page Start:
e1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. (September 2018)

Authors:
Buse, Dawn C; Lipton, Richard B; Hallström, Yngve; Reuter, Uwe; Tepper, Stewart J; Zhang, Feng; Sapra, Sandhya; Picard, Hernan; Mikol, Daniel D; Lenz, Robert A
Journal:
Cephalalgia
Issue:
Volume 38:Number 10(2018)
Page Start:
1622
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. (January 2020)

Authors:
Brandes, Jan Lewis; Diener, Hans-Christoph; Dolezil, David; Freeman, Marshall C; McAllister, Peter J; Winner, Paul; Klatt, Jan; Cheng, Sunfa; Zhang, Feng; Wen, Shihua; Ritter, Shannon; Lenz, Robert A; Mikol, Daniel D
Journal:
Cephalalgia
Issue:
Volume 40:Number 1(2020)
Page Start:
28
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗